References
- Andemariam B, Psaila B, Bussel JB. Novel thrombopoietic agents. Hematology 2007;106–113.
- Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2010 Aug 23. [Epub ahead of print]
- Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010;363:1889–1899.
- Thompson CA. FDA approves thrombopoiesis-stimulating agent. Am J Health Syst Pharm 2008;65:1788.
- Sekeres MA, Kantarjian H, Fenaux P, et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer 2010 Oct 13. [Epub ahead of print]
- Duchez P, Chevaleyre J, Vlaski M, et al. Thrombopoietin to replace megakaryocyte-derived growth factor: impact on stem and progenitor cells during ex vivo expansion of CD34+ cells mobilized in peripheral blood. Transfusion 2010 Aug 23. [Epub ahead of print]
- Koehrer S, Keating MJ, Wierda WG. Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Leukemia 2010;24:1096–1098.
- D'Arena G, Cascavilla N. Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia. Leuk Lymphoma 2011;52: 701–704.
- Connie LM, Jennifer K, Manuel A, Richard M, Parrish P, Antony C. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk Res 2010;34:1224–1231.
- Koller C, Bekele BN, Zhou X, et al. Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia. Blood 2006;108:1001–1006.
- Molica S, Vitelli G, Cutrona G, et al. Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia. Leuk Lymphoma 2008;49:62–67.
- Pulte D, Olson K, Broekman MJ, et al. CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia. J Transl Med 2007;5:23.
- Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010;116:4639–4645.